stockportfolio.pro
BillionToOne, Inc. (BLLN)
Healthcare · Diagnostics & Research · NasdaqGS
BillionToOne, Inc. revenue & earnings — last 3 fiscal years
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $71.73M | $152.58M | $305.11M |
| Gross profit | $17.31M | $80.92M | $208.46M |
| Net income | $-82.68M | $-41.57M | $7.45M |
| Net margin | -115.3% | -27.2% | 2.4% |
Source: BillionToOne, Inc. SEC filings (10-K).
What growth is priced into BLLN stock?
At today's market cap of $4.61B, BillionToOne, Inc. is priced for free-cash-flow growth of about 45.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $15.67M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 3 years of BillionToOne, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BLLN in your portfolio →
BillionToOne, Inc. financial history by metric
About BillionToOne, Inc.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
BillionToOne, Inc. — frequently asked questions
What is BillionToOne, Inc.'s revenue?
BillionToOne, Inc. (BLLN) reported revenue of $305.11M for fiscal year 2025, up 100.0% from the prior year, according to its SEC filings.
Is BillionToOne, Inc. profitable?
Yes. BLLN earned net income of $7.45M in fiscal 2025, a net margin of 2.4%.
What is BLLN's P/E ratio?
BillionToOne, Inc. trades at a price-to-earnings ratio of about 182.3 based on the latest data in our nightly-refreshed cache.
How fast is BillionToOne, Inc. growing?
BLLN's revenue grew at roughly 106.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does BillionToOne, Inc. have?
As of fiscal year 2025, BLLN carried roughly $57.23M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is BillionToOne, Inc.'s gross margin?
BLLN's gross margin was 68.3% in fiscal 2025 — gross profit of $208.46M on revenue of $305.11M.
What is BillionToOne, Inc.'s market cap?
BillionToOne, Inc. (BLLN) has a market capitalization of about $4.61B, based on the latest data in our nightly-refreshed cache.
When does BillionToOne, Inc.'s fiscal year end?
BLLN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BLLN stock?
At today's market cap of $4.61B, BillionToOne, Inc. is priced for free-cash-flow growth of about 45.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $15.67M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from BillionToOne, Inc.'s official SEC filings (10-K and 10-Q), covering 3 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.